Abstract 5374
Background
We aimed to validate the prognostic effects of the metastatic lymph nodes ratio (LNR) in patients with gastric neuroendocrine tumour (G-NET), and establish a nomogram to predict the survival of patients.
Methods
A total of 315 patients with G-NET in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015 were included. Pearson correlation and Cox regression were performed to identify the association between LNR and survival. Nomograms were adopted to predict overall survival (OS) and cancer-specific survival (CSS).
Results
LNR has a negative correlation with OS and CSS (Pearson correlation coefficients: 0.343, P < 0.001; 0.389, P < 0.001, respectively). The multivariate analyses indicated age, tumour site, differentiation, T staging, M staging, chemotherapy and LNR were independent prognostic factors for both OS and CSS. The concordance index (C-index) of the nomograms for OS and CSS were superior to those of the TNM classification (0.773 vs. 0.731; 0.807 vs. 0.769, respectively). According to the area under the ROC curve (AUC), the predictive ability of the new nomogram for 3- and 5-year OS was better than TNM classification (0.908 vs. 0.846, P = 0.004; 0.899 vs. 0.827, P < 0.001, respectively). And the predictive ability of the new nomogram for 1-, 3- and 5-year CSS was better than TNM classification (0.936 vs. 0.848, P = 0.007; 0.910 vs. 0.855, P = 0.003; 0.894 vs. 0.836, P = 0.001, respectively).
Conclusions
LNR was an independent predictor of OS and CSS in G-NET. The nomograms based on the LNR were superior to the TNM classification in predicting the clinical outcomes for G-NET patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yaobin Lin.
Funding
The Fujian Province Natural Science Foundation (2017J01260), Joint Funds for the Innovation of Science and Technology, Fujian province (2017Y9074), and the Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing (2017 Open Project-9).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2667 - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC).
Presenter: Takeshi Kawakami
Session: Poster Display session 2
Resources:
Abstract
3139 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy.
Presenter: Nieves Martinez Lago
Session: Poster Display session 2
Resources:
Abstract
3446 - Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
Presenter: Pasquale Lombardi
Session: Poster Display session 2
Resources:
Abstract
3969 - Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer
Presenter: Kanjana Sukhokanjanachusak
Session: Poster Display session 2
Resources:
Abstract
4455 - Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
Presenter: Shukui Qin
Session: Poster Display session 2
Resources:
Abstract
4481 - Undetectable RAS mutant clones in plasma: possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?
Presenter: Mohamed Bouchahda
Session: Poster Display session 2
Resources:
Abstract
5074 - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: a single Spanish hospital experience.
Presenter: Maria Dolores Mediano Rambla
Session: Poster Display session 2
Resources:
Abstract
5242 - Differences in survival between right and left-sided colorrectal cancer (CRC) in every stage, a CARESS-CCR Group Study.
Presenter: Julia Alcaide-Garcia
Session: Poster Display session 2
Resources:
Abstract
1123 - Quality of Life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC) – Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)
Presenter: Roger von Moos
Session: Poster Display session 2
Resources:
Abstract
1212 - The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: an Italian healthcare payer perspective
Presenter: Karl Patterson
Session: Poster Display session 2
Resources:
Abstract